These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 35129002)

  • 21. Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer: Real-World Incidence, Risk Factors, and Management Practices Across Six Health Care Centers in North Carolina.
    Atchley WT; Alvarez C; Saxena-Beem S; Schwartz TA; Ishizawar RC; Patel KP; Rivera MP
    Chest; 2021 Aug; 160(2):731-742. PubMed ID: 33621599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
    Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
    JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
    Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute hospital-based services used by adults during the last year of life in New South Wales, Australia: a population-based retrospective cohort study.
    Goldsbury DE; O'Connell DL; Girgis A; Wilkinson A; Phillips JL; Davidson PM; Ingham JM
    BMC Health Serv Res; 2015 Dec; 15():537. PubMed ID: 26637373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The utilization of palliative care in gynecologic oncology patients near the end of life.
    Fauci J; Schneider K; Walters C; Boone J; Whitworth J; Killian E; Straughn JM
    Gynecol Oncol; 2012 Oct; 127(1):175-9. PubMed ID: 22735789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Magnitude and Effects of Early Integration of Palliative Care Into Oncology Service Among Adult Advanced Cancer Patients at a Tertiary Care Hospital.
    Ghabashi EH; Sharaf BM; Kalaktawi WA; Calacattawi R; Calacattawi AW
    Cureus; 2021 May; 13(5):e15313. PubMed ID: 34211813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance to immune checkpoint inhibitors in advanced lung cancer: Clinical characteristics, potential prognostic factors and next strategy.
    Zhou J; Lu X; Zhu H; Ding N; Zhang Y; Xu X; Gao L; Zhou J; Song Y; Hu J
    Front Immunol; 2023; 14():1089026. PubMed ID: 36776868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early palliative/supportive care in acute myeloid leukaemia allows low aggression end-of-life interventions: observational outpatient study.
    Potenza L; Scaravaglio M; Fortuna D; Giusti D; Colaci E; Pioli V; Morselli M; Forghieri F; Bettelli F; Messerotti A; Catellani H; Gilioli A; Marasca R; Borelli E; Bigi S; Longo G; Banchelli F; D'Amico R; L Back A; Efficace F; Bruera E; Luppi M; Bandieri E
    BMJ Support Palliat Care; 2021 Nov; ():. PubMed ID: 34750145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Palliative care patient emergency department visits at tertiary university-based emergency department in Ireland.
    Nordt SP; Ryan JM; Kelly D; Kutubi A; Saleh R; Quinn C; Al Kharusi T; Tiernan EJ
    Am J Emerg Med; 2023 Apr; 66():76-80. PubMed ID: 36736062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer.
    Watanabe H; Kubo T; Ninomiya K; Kudo K; Minami D; Murakami E; Ochi N; Ninomiya T; Harada D; Yasugi M; Ichihara E; Ohashi K; Fujiwara K; Hotta K; Tabata M; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2019 Aug; 49(8):762-765. PubMed ID: 31090906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Palliative care needs of advanced cancer patients in the emergency department at the end of life: an observational cohort study.
    Verhoef MJ; de Nijs E; Horeweg N; Fogteloo J; Heringhaus C; Jochems A; Fiocco M; van der Linden Y
    Support Care Cancer; 2020 Mar; 28(3):1097-1107. PubMed ID: 31197539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.
    Halle BR; Betof Warner A; Zaman FY; Haydon A; Bhave P; Dewan AK; Ye F; Irlmeier R; Mehta P; Kurtansky NR; Lacouture ME; Hassel JC; Choi JS; Sosman JA; Chandra S; Otto TS; Sullivan R; Mooradian MJ; Chen ST; Dimitriou F; Long G; Carlino M; Menzies A; Johnson DB; Rotemberg VM
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34635495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors.
    Guven DC; Sahin TK; Aksun MS; Taban H; Aktepe OH; Aksu NM; Akkaş M; Erman M; Kilickap S; Dizdar O; Aksoy S
    Support Care Cancer; 2021 Apr; 29(4):2029-2035. PubMed ID: 32851486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting.
    Durbin SM; Zubiri L; Niemierko A; Bardia A; Sullivan RJ; McEwen C; Mulvey TM; Allen IM; Lawrence DP; Cohen JV; Hochberg EP; Ryan DP; Petrillo LA; Reynolds KL
    Oncologist; 2021 Jan; 26(1):49-55. PubMed ID: 33044765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012-2018.
    Wolf A; Stratmann JA; Shaid S; Niklas N; Calleja A; Ubhi H; Munro R; Waldenberger D; Carroll R; Daumont MJ; Penrod JR; Lacoin L; Rohde G
    BMC Pulm Med; 2023 Jan; 23(1):16. PubMed ID: 36639770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.
    Schett A; Rothschild SI; Curioni-Fontecedro A; Krähenbühl S; Früh M; Schmid S; Driessen C; Joerger M
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):121-131. PubMed ID: 31745593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.
    Rousseau A; Tagliamento M; Auclin E; Aldea M; Frelaut M; Levy A; Benitez JC; Naltet C; Lavaud P; Botticella A; Grecea M; Chaput N; Barlesi F; Planchard D; Besse B
    Eur J Cancer; 2023 Mar; 182():107-114. PubMed ID: 36758475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective cohort study assessing aggressive interventions at the end-of-life among patients with solid metastatic cancer.
    Malhotra C; Bundoc F; Chaudhry I; Teo I; Ozdemir S; Finkelstein E;
    BMC Palliat Care; 2022 May; 21(1):73. PubMed ID: 35578270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aggressive Care at the End of Life; Where Are We?
    Mohammed AA; Al-Zahrani O; Salem RA; Elsayed FM
    Indian J Palliat Care; 2019; 25(4):539-543. PubMed ID: 31673209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.